PRECISION BIOSCIENCES INC
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
About Precision Biosciences
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a clinical-stage genome editing biotechnology company that develops in vivo gene editing therapies using its proprietary ARCUS platform. Its technology enables complex genetic modifications, such as inserting functional genes, eliminating viral genomes, and excising defective genetic sequences. The company's primary internal drug candidates include PBGENE-HBV, aimed at treating chronic hepatitis B by eliminating viral DNA, and PBGENE-DMD, designed to treat Duchenne muscular dystrophy through targeted gene excision. Additionally, the company collaborates with external pharmaceutical partners on programs such as ECUR-506 for ornithine transcarbamylase deficiency, and licenses its technology for therapeutic research and development. Its end customers and beneficiaries are patients suffering from severe genetic disorders and infectious diseases.
The organization conducts clinical trials across several regions, including the United States, New Zealand, Hong Kong, Moldova, Australia, and Spain. Its workforce includes nineteen full-time personnel holding doctoral or medical degrees. The provided text does not identify the location of the corporate headquarters.
Summary of the business section of Precision Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PRECISION BIOSCIENCES INC
- Headquarters
- Durham, NC
- Address
- 302 East Pettigrew Street, Suite A-100 27701
- Phone
- (919) 314-5512
- Website
- precisionbiosciences.com
- Employees
- 68, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- May 21
- Auditor
- Deloitte & Touche LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- DTIL
- Exchange
- Nasdaq
- IPO date
- Mar 28, 2019
- Shares outstanding
- 28M, Aug 3, 2026
- Public float
- $47.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Feb 14, 2024; 1-for-30 reverse, Feb 13, 2024
- SEC CIK
- 1357874
- CUSIP
- 74019P207
- ISIN
- US74019P2074
- LEI
- 549300I5QGRS3BLHZH41
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Amoroso | President and CEO, Director | 243,392 |
| Naresh Haresh Tanna | Chief Financial Officer | 25,575 |
| Cassandra Louise Gorsuch | Chief Scientific Officer | 16,028 |
| Mei Zhang Lu Burris | Chielf Accounting Officer | 5,115 |
| J. Jefferson Smith | Chief Research Officer | 129,857 |
| John Alexander Kelly | Chief Financial Officer | 125,883 |
| Dario Scimeca | General Counsel and Secretary | 56,457 |
| Stanley Frankel | Director | 41,478 |
| Geno J. Germano | Director | 47,492 |
| Melinda Brown | Director | 45,481 |
| Kevin Buehler | Director | 49,137 |
| Shari Lisa Pire | Director | 35,028 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Amoroso | $2.19M | $2.26M | $1.02M | $12 | – |
| FY2024 Mr.Amoroso | $4.31M | $2.00M | $1.67M | $11 | – |
| FY2023 Mr.Amoroso | $2.04M | -$206.56K | $997.18K | $31 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 68 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 25, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 16, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 28, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 28, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 19, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |